CD274 and neoplasm: Decreasing the levels of immunosuppressive factors that limit the T-cell response in the tumor microenvironment or improving the trafficking of activated tumor-specific T cells to tumors may broaden and increase the antitumor response to PD-1/PD-L1 inhibition.14